Magellan Diagnostics specializes in lead testing technologies designed to identify and protect individuals, particularly children, from the harmful effects of lead exposure. Their flagship product, LeadCare II, is a CLIA-waived device that provides rapid lead testing results in just three minutes using a simple fingerstick method. This technology is particularly beneficial in clinical settings, as it integrates seamlessly into office workflows, allowing healthcare providers to deliver timely results without the need for separate lab visits. The ease of use and quick turnaround time make LeadCare II an essential tool for early diagnosis and intervention, which is crucial in preventing the adverse health effects associated with lead poisoning.

In addition to LeadCare II, Magellan offers a range of products tailored to different testing volumes and needs, including LeadCare Plus and LeadCare Ultra. These products are designed to accommodate various healthcare settings, from high-volume practices to point-of-care testing environments. The company emphasizes the importance of early detection and public health education, enabling healthcare providers to engage families effectively and initiate follow-up care promptly. By focusing on accessibility and accuracy, Magellan Diagnostics aims to mitigate the risks of lead exposure and promote healthier outcomes for at-risk populations.

United States

Magellan Diagnostics is a medical device company that provides point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing.

Magellan Diagnostics

Company Details